For decades now, Americans have made clear that lowering the cost of prescription drugs is a key issue for them — and across party lines.
The national organizations leading the push for lower prescription drug prices today sent a joint letter to Congress calling on them to pass legislation to lower prescription drug prices by passing H.R. 3, the Lower Drug Costs Now Act, this year.
In the first three months of the year, the pharmaceutical industry spent $92 million lobbying against efforts to protect people from their profiteering. It’s shameful. The fact is, prescription medicines and COVID vaccines can only work if people have affordable access to them. Clearly, that’s not the priority for Big Pharma players, who are more interested in protecting their monopoly patents than saving lives across the globe.
Today, the Biden Administration made clear that the United States will lead by example in the global fight against COVID. This fight can only be won by working together, not allowing the pharmaceutical corporations to dictate who gets access to COVID vaccines and when.
Action to lower drug prices is the last thing Big Pharma wants from lawmakers. Today’s hearing, which includes testimony from patients and healthcare advocates, represents a key step to enacting long-overdue reforms that would increase transparency, accountability and affordability for patients everywhere.
The Biden Administration and congressional Democrats have a once-in-a-generation opportunity to help the millions of Americans still forced to choose between basic necessities and the prescription medicines they need to live healthy lives. While the American Families Plan includes investments that directly respond to the urgent needs of millions of families, the proposal is incomplete without long-overdue measures to make prescription drugs more affordable for every person, no matter who they are, where they live, or how much money they have in their bank account.
This is just the latest shocking and disgusting example of an industry that puts profits above all else. The actions by Mr. Kramer must be immediately and urgently investigated by the Securities and Exchange Commission.
